EGFR and neoplasm: A retrospective study using formalin-fixed and paraffin-embedded tumor specimens suggested that the positive rate of T790M in the TKI plus bevacizumab group was significantly lower than that in the EGFR-TKI monotherapy group (51.5% vs. 35.5%, p = 0.0003) [56].